Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Filings indexed 338 across all filing types
Latest filing 2025-05-15 Annual Report
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
FORM 20-F
Annual Report FY 2024
2025-05-15 English
FORM 6-K
Regulatory Filings
2025-05-12 English
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Regulatory Filings Classification · 98% confidence The document is titled "Ad Hoc Announcement Pursuant to Art. 53 LR" and is dated May 12, 2025. It discusses a partner (Indivior) successfully advancing a GABAB PAM program through IND enabling studies and provides updates on Addex's own programs. It includes quotes from the CEO, details on a research collaboration agreement, and standard company boilerplate information, including a reference to the Annual Report on Form 20-F in the forward-looking statements section. This format is characteristic of a press release announcing significant operational or partnership milestones, which typically falls under the category of a general regulatory announcement or an earnings-related update, but since it is not a formal earnings release (ER) or a comprehensive quarterly report (IR), and it is not explicitly announcing the publication of a report (RPA), the most appropriate general category for an unscheduled, material operational update is Regulatory Filings (RNS), as it is an 'Ad Hoc Announcement' required by listing rules (LR). Given the content is a substantive business update rather than a simple notification of a report release, RNS is the best fit among the provided options for a non-standard, material announcement.
2025-05-12 English
NT 20-F
Regulatory Filings
2025-04-30 English
FORM 6-K
Regulatory Filings
2025-04-30 English
FORM 6-K
Regulatory Filings
2025-04-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.